人表皮生长因子受体2低表达和零表达乳腺癌患者的临床特征及预后影响因素分析  

Analysis of clinical features and prognostic factors in breast cancer patients with low and zero expression of human epidermal growth factor receptor 2

作　　者：魏修兴 李文炼[1] WEI Xiuxing;LI Wenian(Department of Breast Surgery,Zhongshan Hospital Xiamen University,Xiamen 361004,Fujian,China)

机构地区：[1]厦门大学附属中山医院乳腺外科,福建厦门3610040

出　　处：《癌症进展》2024年第9期999-1003,共5页Oncology Progress

摘　　要：目的目的探讨人表皮生长因子受体2(HER2)低表达和零表达乳腺癌患者的临床特征及预后影响因素。方法根据免疫组织化学法(IHC)检测结果将653例HER2阴性乳腺癌患者分为HER2低表达和HER2零表达患者,比较HER2低表达和HER2零表达乳腺癌患者的临床特征和生存情况,采用Cox比例风险模型分析HER2阴性乳腺癌患者无病生存期(DFS)和总生存期(OS)的影响因素。结果结果HER2低表达乳腺癌患者的激素受体(HR)阳性表达率明显高于HER2零表达患者,差异有统计学意义(P﹤0.01)。HER2低表达和HER2零表达乳腺癌患者的总生存情况和无病生存情况比较,差异均无统计学意义(P﹥0.05)。TNM分期为Ⅲ期、Ki-67≥14%均是HER2阴性乳腺癌患者OS和DFS的独立危险因素(P﹤0.05)。结论结论HER2低表达乳腺癌患者的HR阳性表达率较高,但目前HER2低表达仍然不能被认为是与预后相关的新的分子亚型。TNM分期为Ⅲ期、Ki-67≥14%均是HER2阴性乳腺癌患者OS和DFS的独立危险因素,可以作为HER2阴性乳腺癌患者治疗策略的参考依据。Objective To investigate the clinical features and prognostic factors in breast cancer patients with low and zero expression of human epidermal growth factor receptor 2(HER2).Method A total of 653 HER2 negative breast cancer patients were divided into patients with low and zero expression of HER2 according to the result of immunohisto-chemistry(IHC).The clinical features and survival of breast cancer patients with low and zero expression of HER2 were compared.The influencing factors of disease-free survival(DFS)and overall survival(OS)in HER2 negative breast can-cer patients were analyzed by Cox proportional risk model.Result The positive expression rate of hormone receptor(HR)in breast cancer patients with low expression of HER2 was significantly higher than that of patients with zero ex-pression of HER2,and the difference was statistically significant(P<0.01).There were no significant differences in OS and DFS between breast cancer patients with low and zero expression of HER2(P>0.05).TNM stage III and Ki-67≥14%were independent risk factors for OS and DFS in HER2 negative breast cancer patients(P<0.05).Conclusion The posi-tive expression rate of HR in breast cancer patients with is higher,but low expression of HER2 can not be considered as new molecular subtype related to prognosis at present.TNM stage III and Ki-67≥14%are independent risk factors for OS and DFS in HER2 negative breast cancer patients,which can be used as a reference for treatment strategies of HER2 nega-tive breast cancer patients.

关 键 词：乳腺癌 人表皮生长因子受体2 预后 临床特征 

分 类 号：R737.9[医药卫生—肿瘤]